Bull Horn Holdings Corp.

Coeptis Therapeutics Holdings, Inc. engages in the development of innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its products portfolio consists of cell therapy technology, CD38-GEAR-NK, and an in vitro diagnostic, CD38-Diagnostic, targeting CD38-related cancer. The company is headquartered in Wexford, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Combined company to operate as Coeptis Therapeutics Holdings, Inc. and commence trading on The Nasdaq Global Market under Ticker Symbol "COEP" WEXFORD, Pa. and MIAMI , Oct. 31, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. ("Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings Corp. (Nasdaq: BHSE), a special purpose acquisition company ("Bull Horn").

Coeptis Therapeutics, Inc. Announces Closing of Business Combination with Bull Horn Holdings Corp.

SNAP-CAR therapy provides a highly programmable therapeutic platform designed to potentially target many tumor types, including hematological malignancies and solid tumors WEXFORD, Pa. , Sept. 21, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC PINK: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive license agreement with the University of Pittsburgh for the rights to a chimeric antigen receptor T cell (CAR T) technology – SNAP-CAR – designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including breast and ovarian cancer.

Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology

Coeptis Therapeutics Holdings, Inc.

Many sponsors face challenges as they race the clock to find a target amid regulatory crackdown and waning enthusiasm.

This SPAC is merging with an already-public company as sponsors get creative before time runs out

Transaction expected to accelerate Coeptis' ability to progress its innovative cell therapy platforms for cancer David Mehalick of Coeptis to serve as Chief Executive Officer;  Chris Calise of Bull Horn to join the Board of Directors Merger anticipated to close in third quarter 2022; combined company anticipated to list on Nasdaq WEXFORD, Pa., and MIAMI, Fla.

Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement

MIAMI BEACH, Fla.--(BUSINESS WIRE)--Bull Horn Holdings Corp. (NASDAQ: BHSE) (the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the “Form 10-Q”) in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq's continued listing requirements under the timely fi

Bull Horn Holdings Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Omnichannel Acquisition Corp.

Soaring Eagle Acquisition Corp - Unit

Spac Guru, a well-known name in the SPAC space, joined SPACs Attack last week to share thoughts on the overall SPAC market. Spac Guru also shared three undervalued SPAC picks with viewers of the show.

3 Undervalued SPAC Picks From The Spac Guru

Acri Capital Acquisition Corp

IG Acquisition Corp.

RedBall Acquisition Corp.

Sports Entertainment Acquisition Corp.

The SPAC market continues to offer new opportunities for investors to invest based on management teams and target areas of acquisition. Here is a look at six SPACs targeting the sports sector.

6 Sports SPACs To Consider For Your Investing Playbook

MIAMI BEACH, Fla.--(BUSINESS WIRE)--Bull Horn Holdings Corp. (NASDAQ: BHSEU) (the “Company”) announced today that, commencing December 17, 2020, holders of the 7,500,000 units sold in the Company's initial public offering may elect to separately trade the Company's ordinary shares and warrants included in the units. Ordinary shares and warrants that are separated will trade on The Nasdaq Capital Market under the symbols “BHSE” and “BHSEW”, respectively. Those units not separated will continue t

Bull Horn Holdings Corp. Announces Separate Trading of its Ordinary Shares and Warrants, Commencing December 17, 2020

MIAMI--(BUSINESS WIRE)--Bull Horn Holdings Corp. (the “Company”) today announced the closing of its initial public offering of 7,500,000 units. The offering was priced at $10.00 per unit, resulting in gross proceeds of $75,000,000. Bull Horn Holdings Corp. is a blank check company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue a busines

Bull Horn Holdings Corp. Completes $75 Million Initial Public Offering

News for Bull Horn Holdings Corp. Stock (BHSE)